The Experts below are selected from a list of 129 Experts worldwide ranked by ideXlab platform

Arsène Burny - One of the best experts on this subject based on the ideXlab platform.

  • Vaccination against δ−RetroViruses: The Bovine Leukemia Virus Paradigm
    Viruses, 2014
    Co-Authors: Gerónimo Gutiérrez, Arsène Burny, Juan Pablo Jaworski, Irene Alvarez, Sabrina Rodriguez, Alix De Brogniez, Nicolas Gillet, Ramarao Golime, Lucas Vagnoni, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) and human T-lymphotropic Virus type 1 (HTLV-1) are closely related d-retroViruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and Leukemia/lymphoma (adult T-cell Leukemia). Bovine Leukemia Virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroViruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.

  • vaccination against δ retroViruses the Bovine Leukemia Virus paradigm
    Viruses, 2014
    Co-Authors: Gerónimo Gutiérrez, Arsène Burny, Juan Pablo Jaworski, Irene Alvarez, Sabrina Rodriguez, Alix De Brogniez, Nicolas Gillet, Ramarao Golime, Lucas Vagnoni, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) and human T-lymphotropic Virus type 1 (HTLV-1) are closely related d-retroViruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and Leukemia/lymphoma (adult T-cell Leukemia). Bovine Leukemia Virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroViruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.

  • Enzootic Bovine Leukosis and Bovine Leukemia Virus
    2012
    Co-Authors: Arsène Burny, Marc Mammerickx
    Abstract:

    Enzootic Bovine leukosis (EBL) is a lymphoproliferative disease of cattle characterized by persistent lymphocytosis (too high number of lymphocytes) and (or) by the development of lymph nodes tumours (1). EBL is contagious among cattle and experimentally transmissible to cattle, sheep and some other animal species. It affects B lymphocytes and is induced by a Virus called Bovine Leukemia Virus (BLV) (2).

  • Genetic Determinants of Bovine Leukemia Virus Pathogenesis
    AIDS research and human retroviruses, 2000
    Co-Authors: Luc Willems, Arsène Burny, Delphine Collete, Olivier Dangoisse, Franck Dequiedt, Jean-stéphane Gatot, Pierre Kerkhofs, Laurent Lefèbvre, C. Merezak, T. Peremans
    Abstract:

    The understanding of HTLV-induced disease is hampered by the lack of a suitable animal model allowing the study of both viral replication and leukemogenesis in vivo. Although valuable information has been obtained in different species, such as rabbits, mice, rats, and monkeys, none of these systems was able to conciliate topics as different as viral infectivity, propagation within the host, and generation of leukemic cells. An alternate strategy is based on the understanding of diseases induced by Viruses closely related to HTLV-1, like Bovine Leukemia Virus (BLV). Both Viruses indeed belong to the same subfamily of retroViruses, harbor a similar genomic organization, and infect and transform cells of the hematopoietic system. The main advantage of the BLV system is that it allows direct experimentation in two different species, cattle and sheep.

  • Fusion of Bovine Leukemia Virus with target cells monitored by R18 fluorescence and PCR assays.
    Journal of virology, 1997
    Co-Authors: S. Zarkik, Arsène Burny, Daniel Portetelle, F. Defrise-quertain, Jm. Ruysschaert
    Abstract:

    PCR and R18 fluorescence dequenching assays have been combined to monitor the kinetics of fusion of Bovine Leukemia Virus with target cells (CC81, OVK, or Raji). Antibodies raised against gp51 allow us to demonstrate that not only the hydrophobic N-terminal domain of the transmembrane glycoprotein gp30 but also specific domains of gp51 (amino acids 39 to 103) are involved in Bovine Leukemia Virus-cell fusion.

Karina Trono - One of the best experts on this subject based on the ideXlab platform.

  • Quantification of Cell Turnover in the Bovine Leukemia Virus Model
    Methods in molecular biology (Clifton N.J.), 2017
    Co-Authors: Alix De Brogniez, Gerónimo Gutiérrez, Karina Trono, Michal Reichert, Pierre-yves Barez, Alexandre Carpentier, Luc Willems
    Abstract:

    In a perspective of a comparative virology approach, characterization of the Bovine Leukemia Virus (BLV) model may be helpful to better understand infection by the related human T-lymphotropic Virus type 1 (HTLV-1). In this paper, we first provide detailed protocols to inoculate cloned BLV proViruses into sheep or cattle. We also describe methods to quantify apoptosis ex vivo and cell turnover in vivo.

  • Short communication: Relationship between the level of Bovine Leukemia Virus antibody and proVirus in blood and milk of cows from a naturally infected herd
    Journal of Dairy Science, 2016
    Co-Authors: Juan Pablo Jaworski, Natalia Gabriela Porta, Gerónimo Gutiérrez, Romina Politzki, Irene Alvarez, R. Galarza, Alejandro Abdala, Luis F. Calvinho, Karina Trono
    Abstract:

    We explored the relationship between the level of Bovine Leukemia Virus antibodies and proVirus load during natural infection. For that purpose, a set of 50 blood and milk paired samples were analyzed for the presence of Bovine Leukemia Virus proVirus and antibodies. Additionally, proVirus load and antibody titers were measured and the relationship between these variables was investigated. Bovine Leukemia proVirus was detected in 59% of milk samples and a negative correlation was observed between the level of milk proVirus load and milk antibody titers. By the consumption of raw milk, calves might be exposed to Bovine Leukemia Virus favoring the perinatal transmission of this disease.

  • Vaccination against δ−RetroViruses: The Bovine Leukemia Virus Paradigm
    Viruses, 2014
    Co-Authors: Gerónimo Gutiérrez, Arsène Burny, Juan Pablo Jaworski, Irene Alvarez, Sabrina Rodriguez, Alix De Brogniez, Nicolas Gillet, Ramarao Golime, Lucas Vagnoni, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) and human T-lymphotropic Virus type 1 (HTLV-1) are closely related d-retroViruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and Leukemia/lymphoma (adult T-cell Leukemia). Bovine Leukemia Virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroViruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.

  • vaccination against δ retroViruses the Bovine Leukemia Virus paradigm
    Viruses, 2014
    Co-Authors: Gerónimo Gutiérrez, Arsène Burny, Juan Pablo Jaworski, Irene Alvarez, Sabrina Rodriguez, Alix De Brogniez, Nicolas Gillet, Ramarao Golime, Lucas Vagnoni, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) and human T-lymphotropic Virus type 1 (HTLV-1) are closely related d-retroViruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and Leukemia/lymphoma (adult T-cell Leukemia). Bovine Leukemia Virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroViruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.

  • Egg yolk antibodies (IgY) against Bovine Leukemia Virus
    Retrovirology, 2014
    Co-Authors: Cecilia Martínez, Natalia Gabriela Porta, Gerónimo Gutiérrez, Irene Alvarez, Marina Lomonaco, Andrés Wigdorovitz, Pablo Chacana, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) is distributed worldwide and causes important economic losses on dairy farms. Currently, there are no effective vaccines or antivirals against BLV. Egg yolk antibodies (IgY) has many advantages over mammalian IgG. Despite the higher yields, they are non-invasively extracted from egg yolk, do not cross react against mammalian antigens or activate the mammalian complement system. In this work we evaluate the reactivity of Igy antibodies against Bovine Leukemia Virus p24 core protein and against the whole Virus particle. Hens were immunized by intramuscular inoculation with purified p24 or the Virus particle until the development of high antibody-titers. Total IgY was purified from egg yolks by ammonium sulfate precipitation. The purified egg yolk antibodies strongly reacted with BLV particles from a persistently infected cell line, with supernatants from ex vivo cultures of PBMCs from natural infected animals and also with purified p24 by both ELISA and Western blot. These data suggest that chicken IgY may be a suitable platform to produce large amounts of anti-BLV antibodies for diagnostic systems. Furthermore, the use of IgY for passive immunization against BLV infection should also be explored in order to develop new strategies to control the disease in cattle.

J W Casey - One of the best experts on this subject based on the ideXlab platform.

  • Assessment of Bovine Leukemia Virus Transcripts In Vivo
    Journal of virology, 1999
    Co-Authors: Joel Rovnak, J W Casey
    Abstract:

    Reverse transcriptase PCR (RT-PCR) consistently detected Bovine Leukemia Virus transcripts in fresh cells, and competitive RT-PCR enumerated these transcripts. The detection of transcripts in limited numbers of tumor cells indicated that expression occurs in a minority of cells. The data suggest that individual cells contain hundreds of copies of the tax/rex transcript in vivo.

  • Bovine Leukemia Virus gene expression in vivo.
    Journal of virology, 1992
    Co-Authors: L Haas, T Divers, J W Casey
    Abstract:

    The in vivo transcriptional status of Bovine Leukemia Virus was assessed at three stages of infection during the progression of the disease: aleukemic stage, persistent lymphocytosis, and Leukemia/lymphosarcoma. Bovine Leukemia Virus transcripts could be amplified from total or cytoplasmic enriched lymphocyte RNA by reverse transcription polymerase chain reaction in cells from all but a few aleukemic animals. With primer pairs diagnostic for differentially spliced transcripts (full length-genomic, envelope, tax/rex, and alternatively spliced), a trend toward exclusion of both full-length and envelope RNAs, with retention of the tax/rex message, appears as Leukemia/lymphosarcoma develops.

Gerónimo Gutiérrez - One of the best experts on this subject based on the ideXlab platform.

  • Quantification of Cell Turnover in the Bovine Leukemia Virus Model
    Methods in molecular biology (Clifton N.J.), 2017
    Co-Authors: Alix De Brogniez, Gerónimo Gutiérrez, Karina Trono, Michal Reichert, Pierre-yves Barez, Alexandre Carpentier, Luc Willems
    Abstract:

    In a perspective of a comparative virology approach, characterization of the Bovine Leukemia Virus (BLV) model may be helpful to better understand infection by the related human T-lymphotropic Virus type 1 (HTLV-1). In this paper, we first provide detailed protocols to inoculate cloned BLV proViruses into sheep or cattle. We also describe methods to quantify apoptosis ex vivo and cell turnover in vivo.

  • Short communication: Relationship between the level of Bovine Leukemia Virus antibody and proVirus in blood and milk of cows from a naturally infected herd
    Journal of Dairy Science, 2016
    Co-Authors: Juan Pablo Jaworski, Natalia Gabriela Porta, Gerónimo Gutiérrez, Romina Politzki, Irene Alvarez, R. Galarza, Alejandro Abdala, Luis F. Calvinho, Karina Trono
    Abstract:

    We explored the relationship between the level of Bovine Leukemia Virus antibodies and proVirus load during natural infection. For that purpose, a set of 50 blood and milk paired samples were analyzed for the presence of Bovine Leukemia Virus proVirus and antibodies. Additionally, proVirus load and antibody titers were measured and the relationship between these variables was investigated. Bovine Leukemia proVirus was detected in 59% of milk samples and a negative correlation was observed between the level of milk proVirus load and milk antibody titers. By the consumption of raw milk, calves might be exposed to Bovine Leukemia Virus favoring the perinatal transmission of this disease.

  • Vaccination against δ−RetroViruses: The Bovine Leukemia Virus Paradigm
    Viruses, 2014
    Co-Authors: Gerónimo Gutiérrez, Arsène Burny, Juan Pablo Jaworski, Irene Alvarez, Sabrina Rodriguez, Alix De Brogniez, Nicolas Gillet, Ramarao Golime, Lucas Vagnoni, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) and human T-lymphotropic Virus type 1 (HTLV-1) are closely related d-retroViruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and Leukemia/lymphoma (adult T-cell Leukemia). Bovine Leukemia Virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroViruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.

  • vaccination against δ retroViruses the Bovine Leukemia Virus paradigm
    Viruses, 2014
    Co-Authors: Gerónimo Gutiérrez, Arsène Burny, Juan Pablo Jaworski, Irene Alvarez, Sabrina Rodriguez, Alix De Brogniez, Nicolas Gillet, Ramarao Golime, Lucas Vagnoni, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) and human T-lymphotropic Virus type 1 (HTLV-1) are closely related d-retroViruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and Leukemia/lymphoma (adult T-cell Leukemia). Bovine Leukemia Virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroViruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.

  • Egg yolk antibodies (IgY) against Bovine Leukemia Virus
    Retrovirology, 2014
    Co-Authors: Cecilia Martínez, Natalia Gabriela Porta, Gerónimo Gutiérrez, Irene Alvarez, Marina Lomonaco, Andrés Wigdorovitz, Pablo Chacana, Karina Trono
    Abstract:

    Bovine Leukemia Virus (BLV) is distributed worldwide and causes important economic losses on dairy farms. Currently, there are no effective vaccines or antivirals against BLV. Egg yolk antibodies (IgY) has many advantages over mammalian IgG. Despite the higher yields, they are non-invasively extracted from egg yolk, do not cross react against mammalian antigens or activate the mammalian complement system. In this work we evaluate the reactivity of Igy antibodies against Bovine Leukemia Virus p24 core protein and against the whole Virus particle. Hens were immunized by intramuscular inoculation with purified p24 or the Virus particle until the development of high antibody-titers. Total IgY was purified from egg yolks by ammonium sulfate precipitation. The purified egg yolk antibodies strongly reacted with BLV particles from a persistently infected cell line, with supernatants from ex vivo cultures of PBMCs from natural infected animals and also with purified p24 by both ELISA and Western blot. These data suggest that chicken IgY may be a suitable platform to produce large amounts of anti-BLV antibodies for diagnostic systems. Furthermore, the use of IgY for passive immunization against BLV infection should also be explored in order to develop new strategies to control the disease in cattle.

K. Slavikova - One of the best experts on this subject based on the ideXlab platform.

  • Expression of env gene of Bovine Leukemia Virus in rodent cells
    Archives of Virology, 1994
    Co-Authors: V. Zajac, K. Slavikova, O. Babusikova
    Abstract:

    The BamHI-BamHI fragment of the env gene of Bovine Leukemia Virus (BLV) cloned in pMMEx expression vector was transfected into Chinese hamster cells. Monoclonal antibodies (MAbs) directed against both conformational and sequential epitopes of gp51 of BLV recognized viral polypeptides expressed in hamster cells in Western blotting and enzyme-linked immunosorbent assay.

  • Gp51 of Bovine Leukemia Virus gene expression in hamster cells
    International journal of cancer, 1993
    Co-Authors: K. Slavikova, V. Zajac, Margita Klobušická, Y. Aida, V. Stevurkova
    Abstract:

    Recombinant pMMEx-Bovine Leukemia Virus env gene DNA fragments were produced and expressed in eukaryotic cells. Clone C4, containing an SmaI-SmaI fragment of the gene coding for gp51, was co-transfected with pSV2neo DNA into Chinese hamster cells. About 800 geneticin-resistant cell clones were isolated and then morphologically and biologically characterized. The presence of gp51 encoding env gene fragments was detected in 17 of them by Southern blotting. The expression of gp51 gene in hamster cells was confirmed by Western blotting of their lysates with monoclonal antibodies (MAbs) directed against different epitopes of gp51 of Bovine Leukemia Virus. The immunoreactivity of the expressed peptides with MAbs directed against neutralizing epitopes of gp51 of Bovine Leukemia Virus was confirmed.